Get the Stockscreener App
75.03
0.43%
0.32
Cg Oncology Inc stock is traded at $75.03, with a volume of 596.27K.
It is up +0.43% in the last 24 hours and up +4.54% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$74.71
Open:
$74.54
24h Volume:
596.27K
Relative Volume:
0.58
Market Cap:
$6.65B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-32.03
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
-0.09%
1M Performance:
+4.54%
6M Performance:
+45.69%
1Y Performance:
+189.02%
1-Day Range:
$73.50
$75.66
1-Week Range:
$73.50
$79.39
52-Week Range:
$24.85
$79.39
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
75.03 | 6.82B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CGON shareholder (NASDAQ: CGON) details planned 19,364-share stock sale - Stock Titan
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds - Stock Titan
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - Orange County Business Journal
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares - Stock Titan
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects. - Pluang
CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON) - Seeking Alpha
CGON (CGON) investor lists 25,989-share sale after series of stock disposals - Stock Titan
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position - Stock Titan
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise - Stock Titan
CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale - Stock Titan
CG Oncology (NASDAQ:CGON) Hits New 52-Week HighShould You Buy? - MarketBeat
CGON (CGON) insider plans 50,000-share stock sale after option exercise - Stock Titan
HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings - MarketBeat
CG Oncology Inc (CGON) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $85 to $108 - Moomoo
Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON) - The Globe and Mail
Bank of America Corp DE Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wall Street Zen Downgrades CG Oncology (NASDAQ:CGON) to Strong Sell - MarketBeat
CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS - MarketBeat
Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades - Stock Titan
Royal Bank Of Canada Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
Piper Sandler Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
Truist Financial Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $79 to $100 - Moomoo
BofA Adjusts Price Target on CG Oncology to $88 From $87 - Moomoo
RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating - marketscreener.com
FY2029 EPS Estimates for CG Oncology Cut by HC Wainwright - MarketBeat
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data - simplywall.st
CG ONCOLOGY Q2 NET INCOME USD -79.1 MILLION - Moomoo
CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside - TradingView
Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales - Stock Titan
CG Oncology earnings up next amid bladder cancer therapy push By Investing.com - Investing.com Nigeria
CG Oncology earnings up next amid bladder cancer therapy push - Investing.com
CG Oncology Announces Q2 2026 Financial Results with Increased Revenues and Expanded Marketable Securities - Kalkine Media
CG Oncology Announces Q2 2026 Earnings and Boosts ATM Equity Offering by $500 Million - Kalkine Media
CG Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CG Oncology Q2 Net Loss Widens - marketscreener.com
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.90 a Share, vs. FactSet Est of $0.66 Loss - marketscreener.com
Earnings Flash (CGON) CG Oncology, Inc. Reports Q2 Revenue $1.2M - marketscreener.com
CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash - Stock Titan
CG Oncology posts Q2 loss as bladder cancer milestones approach - Quiver Quantitative
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
CG Oncology Q2 net loss widens on higher R&D costs - TradingView
CG Oncology expects bladder cancer trial data soon; cash through 2029 - Stock Titan
CG Oncology (CGON) Earnings Date and Reports 2026 - MarketBeat
CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programs - Bitget
CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker - stocktitan.net
Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON - MarketBeat
Investors Purchase Large Volume of Call Options on CG Oncology (NASDAQ:CGON) - MarketBeat
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):